Category: Health

Wednesday, May 27, 2020

Neovasc (NVCN)(NVCN:CA)

Neovasc Removes Financing Overhang

As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Retiring 2017 Notes. Neovasc’s management yesterday provided a corporate update and announced several agreements, including a $5 mm financing, and the retirement of 2017 Notes (which had onerous provisions), which we believe improves the Company’s financial position and revamps its capital structure.

The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Management indicated that Pre-Market Approval (PMA) review is progressing as expected. The Company just…

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Wednesday, May 27, 2020

Ceapro (CRPOF)(CZO)

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.


Versatility of Ceapro’s proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and…







Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Wednesday, May 27, 2020

Neovasc (NVCN)(NVCN:CA)

Neovasc Removes Financing Overhang

As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Retiring 2017 Notes. Neovasc’s management yesterday provided a corporate update and announced several agreements, including a $5 mm financing, and the retirement of 2017 Notes (which had onerous provisions), which we believe improves the Company’s financial position and revamps its capital structure.

The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Management indicated that Pre-Market Approval (PMA) review is progressing as expected. The Company just…

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Wednesday, May 27, 2020

Ceapro (CRPOF)(CZO)

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.


Versatility of Ceapro’s proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and…







Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Tuesday, May 26, 2020

Genprex Inc.(GNPX)

Emerging as a Leader in Cancer Gene Therapy

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.


GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….









Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Tuesday, May 26, 2020

Genprex Inc.(GNPX)

Emerging as a Leader in Cancer Gene Therapy

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.


GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….









Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Tuesday, May 19, 2020

electroCore (ECOR)

Q1 2020: Progressing Slowly but Steady

electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Expanding the market potential of gammaCore. In the quarter, electroCore received the 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand gammaCore therapy use for the prevention of migraine in adult patients. The company is also evaluating gammaCore for the treatment of Covid-19 symptoms including difficulty in breathing and cytokine storm. These indications represent a large commercial opportunity for the Company.

Q1 2020 financial update. The company reported $0.7338 mm (+9%) net sales in Q1 2020 compared to $0.675 mm in the previous quarter. The company experienced 19% sequential growth in paid months of therapy, rising to 2,611 in the first quarter of 2020 from 2,195 in the fourth quarter of 2019. The gain in adoption of…








Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Tuesday, May 19, 2020

Dyadic International Inc. (DYAI)

Q1 2020: Continue Progressing on Validation of C1 Platform

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Dyadic has a rich partnership portfolio. Dyadic has established multiple research collaborations assessing C1 technology to improve manufacturing of biologics in human and animal health. The proprietary C1 platform can potentially express various biologic products including Fc-fusion proteins, monoclonal antibodies, Fabs, bi or tri-specifics, gene therapy, vaccines, and others. The company is also evaluating C1 to produce vaccines and antibodies against coronavirus.


C1’s has the potential to be a superior biomanufacturing technology. We believe these partnerships increase the probability of success of the C1 platform in biologic manufacturing. In our opinion, the demonstration of improved cost effectiveness and high yield production from any of the research collaborations or…









Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Tuesday, May 19, 2020

electroCore (ECOR)

Q1 2020: Progressing Slowly but Steady

electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Expanding the market potential of gammaCore. In the quarter, electroCore received the 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand gammaCore therapy use for the prevention of migraine in adult patients. The company is also evaluating gammaCore for the treatment of Covid-19 symptoms including difficulty in breathing and cytokine storm. These indications represent a large commercial opportunity for the Company.

Q1 2020 financial update. The company reported $0.7338 mm (+9%) net sales in Q1 2020 compared to $0.675 mm in the previous quarter. The company experienced 19% sequential growth in paid months of therapy, rising to 2,611 in the first quarter of 2020 from 2,195 in the fourth quarter of 2019. The gain in adoption of…








Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Tuesday, May 19, 2020

Dyadic International Inc. (DYAI)

Q1 2020: Continue Progressing on Validation of C1 Platform

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Dyadic has a rich partnership portfolio. Dyadic has established multiple research collaborations assessing C1 technology to improve manufacturing of biologics in human and animal health. The proprietary C1 platform can potentially express various biologic products including Fc-fusion proteins, monoclonal antibodies, Fabs, bi or tri-specifics, gene therapy, vaccines, and others. The company is also evaluating C1 to produce vaccines and antibodies against coronavirus.


C1’s has the potential to be a superior biomanufacturing technology. We believe these partnerships increase the probability of success of the C1 platform in biologic manufacturing. In our opinion, the demonstration of improved cost effectiveness and high yield production from any of the research collaborations or…









Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Friday, May 15, 2020

Onconova Therapeutics Inc. (ONTX)

Q1 2020 Earnings: 2020 Could Be Transformational for Onconova

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

INSPIRE topline data is set to readout in H2 2020. In Q1 2020, Onconova completed patient enrollment in pivotal Phase 3 INSPIRE trial evaluating rigosertib in 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company plans to present topline data at a major conference (more likely ASH) in H2 2020.


Pipeline diversification in 2020. Besides the INSPIRE study, the company is on track to diversify its pipeline with additional programs including an investigator-initiated study of rigosertib plus nivolumab in Stage IV KRAS mutated lung adenocarcinoma and a randomized Phase 2/3 study of the combination of oral rigosertib plus azacytidine in 1st line HR-MDS patients (anticipated in 2020). Also, IND submission of ON123300 (CDK 4/6 + ARK5 inhibitor) program is anticipated Q4 2020. We believe these programs will generate value and…










Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Friday, May 15, 2020

Helix Biopharma (HBPCF)(HBP:CA)

Phase I Results at ASCO Bode Well for Lead Drug’s Prospects

As of April 24, 2020, Noble Capital Markets research on Helix Biopharma is published under ticker symbols (HBPCF and HBP:CA). The price target is in USD and based on ticker symbol HBPCF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Helix Biopharma presents data at ASCO 2020. Helix BioPharma yesterday announced results from a recently completed Phase I dose escalation clinical trial on the use of L-DOS47, in combination with pemetrexed and carboplatin, for the treatment of a type of lung cancer. The results were published by American Society of Clinical Oncology (ASCO).


Lead drug L-DOS47 shows clinical benefit. Of the twelve patients evaluable for efficacy, 5 patients (42%) had a partial response to treatment, 4 patients (33%) showed stable disease and three patients (25%) had progressive disease. In the trial, the objective response rate was 42% and…









Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Friday, May 15, 2020

Onconova Therapeutics Inc. (ONTX)

Q1 2020 Earnings: 2020 Could Be Transformational for Onconova

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

INSPIRE topline data is set to readout in H2 2020. In Q1 2020, Onconova completed patient enrollment in pivotal Phase 3 INSPIRE trial evaluating rigosertib in 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company plans to present topline data at a major conference (more likely ASH) in H2 2020.


Pipeline diversification in 2020. Besides the INSPIRE study, the company is on track to diversify its pipeline with additional programs including an investigator-initiated study of rigosertib plus nivolumab in Stage IV KRAS mutated lung adenocarcinoma and a randomized Phase 2/3 study of the combination of oral rigosertib plus azacytidine in 1st line HR-MDS patients (anticipated in 2020). Also, IND submission of ON123300 (CDK 4/6 + ARK5 inhibitor) program is anticipated Q4 2020. We believe these programs will generate value and…










Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.